HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BASF's PEG-25 PABA

This article was originally published in The Rose Sheet

Executive Summary

Sunscreen ingredient's monograph status "is dependent on the outcome of [the] broader policy determination" of the acceptability of foreign marketing data and the meaning of "to a material extent and for a material time," FDA tells the German company in a recent letter. The agency says it "anticipates a public rulemaking procedure that may take some time to complete" and pointed out that the company has the option of submitting an NDA for ethoxylated ethyl-4-aminobenzoate (PEG-25 PABA). BASF requested that FDA reopen the administrative record for sunscreens to include PEG-25 PABA as a Category I ingredient ("The Rose Sheet" Feb. 14, p. 7)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel